NKD2 and osteosarcoma: NKD2 is an adapter protein and endogenous inhibitor of Wnt‐β‐catenin signaling [32] and has been described to reduce breast cancer cell proliferation [33] and tumor and metastasis growth in osteosarcoma patients [34].